EUVIMEDEUVIMED entdecken
LeserbriefKohortenstudie

Switching from baricitinib to dupilumab as an advanced‐line treatment in pediatric patients with atopic dermatitis: a retrospective cohort study

Ayelet Ollech, Eran Cohen-Barak, Amir Horev iD, Efrat Bar-Ilan iD, Shoshana Greenberger

International Journal of Dermatology · 2024

DOI: 10.1111/ijd.17198 ↗

Kurz gefasst

Leserbrief in der Zeitschrift International Journal of Dermatology, 2024. Verfasst von Ayelet Ollech und 4 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Dermatology Service, Shaare Zedek Medical Center, Hebrew University of Jerusalem, The Faculty of Medicine, Jerusalem, Israel. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Pyrazoles, Azetidines, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 5 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicPyrazolesAzetidinesAntibodies, Monoclonal, HumanizedSulfonamidesPurinesHumansRetrospective StudiesChildMaleFemaleAdolescentDrug SubstitutionTreatment OutcomeChild, PreschoolSeverity of Illness IndexDermatologic Agents

Stichwörter der Autor:innen

JAK inhibitorsatopic dermatitisbiological treatmentdupilumab baricitinibpediatric patientssystemic treatment

Substanzen

baricitinibdupilumabPyrazolesAzetidinesAntibodies, Monoclonal, HumanizedSulfonamidesPurinesDermatologic Agents

Autor:innen und Institutionen

  • Pediatric Dermatology Service, Shaare Zedek Medical Center, Hebrew University of Jerusalem, The Faculty of Medicine, Jerusalem, Israel.
  • Department of Dermatology, Emek Medical Center, The Ruth and Bruce Rappaport Faculty of Medicine, Haifa, Israel.
  • Pediatric Dermatology Service, Soroka University Medical Center, Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheva, Israel.
  • Pediatric Dermatology Unit, Dermatology Department, Sheba Medical Center, Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

ORCID-Profile: Amir Horev, Efrat Bar-Ilan

Zitieren

APA

Ollech, A., Cohen-Barak, E., Horev, A., Bar-Ilan, E., & Greenberger, S. (2024). Switching from baricitinib to dupilumab as an advanced‐line treatment in pediatric patients with atopic dermatitis: a retrospective cohort study. International Journal of Dermatology. https://doi.org/10.1111/ijd.17198

Vancouver

Ollech A, Cohen-Barak E, Horev A, Bar-Ilan E, Greenberger S. Switching from baricitinib to dupilumab as an advanced‐line treatment in pediatric patients with atopic dermatitis: a retrospective cohort study. International Journal of Dermatology. 2024. doi:10.1111/ijd.17198

BibTeX
@article{Ollech2024,
  author = {Ollech, Ayelet and Cohen-Barak, Eran and Horev, Amir and Bar-Ilan, Efrat and Greenberger, Shoshana},
  title = {Switching from baricitinib to dupilumab as an advanced‐line treatment in pediatric patients with atopic dermatitis: a retrospective cohort study},
  journal = {International Journal of Dermatology},
  year = {2024},
  doi = {10.1111/ijd.17198}
}
Kostenlos starten →